# A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

> **NCT05836324** · PHASE1 · RECRUITING · sponsor: **Incyte Corporation** · enrollment: 408 (estimated)

## Conditions studied

- Solid Tumors
- Advanced Solid Tumors
- Metastatic Solid Tumors

## Interventions

- **DRUG:** INCA33890
- **DRUG:** bevacizumab
- **DRUG:** FOLFIRI
- **DRUG:** FOLFOX
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05836324
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-07-24
- **Primary completion:** 2027-01-13
- **Final completion:** 2027-01-13
- **Target enrollment:** 408 (ESTIMATED)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05836324

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05836324, "A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT05836324. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*